Chimeric antigen receptor (CAR) T‐cell therapy is considered as a major scientific breakthrough in cancer immunotherapy. The success of adoptive CAR T‐cell therapy for cancer has inspired researchers to expand indications into the area of solid tumors, autoimmune and infectious diseases. The most important factors influencing outcome and durability of the response after infusion of CAR T‐cell are proliferation and persistence of this cell subset. It becomes therefore important to detect easily and monitor circulating CAR T‐cells into blood samples. Approaches such as quantitative PCR (qPCR) or flow cytometry have been developed. The aim of this study was to set up and optimize a reachable flow cytometry technique using labeled CD19 protein for the measurement of CAR T‐cells in infusion bag and patient's blood.

中文翻译：

---

使用流式细胞术监测 CAR T 细胞

嵌合抗原受体 (CAR) T 细胞疗法被认为是癌症免疫疗法的重大科学突破。癌症过继性 CAR T 细胞疗法的成功激发了研究人员将适应症扩展到实体瘤、自身免疫和传染病领域。影响输注 CAR T 细胞后反应结果和持久性的最重要因素是该细胞亚群的增殖和持久性。因此，轻松检测和监测血液样本中循环的 CAR T 细胞变得很重要。已经开发了诸如定量 PCR (qPCR) 或流式细胞术等方法。本研究的目的是建立和优化使用标记 CD19 蛋白的可达到的流式细胞术技术，用于测量输液袋和患者血液中的 CAR T 细胞。